Inmagene Starts Phase 2 Alopecia Areata Trial

The alopecia areata pipeline continues to expand with companies reaching the clinical trial stage; an overall good sign for hair-related diseases. This time, Inmagene Biopharmaceuticals has entered a phase 2a clinical trial for its antibody candidate IMG-007 in adults with moderate to severe alopecia areata. IMG-007 is a monoclonal antibody therapy against the 0x40 protein, and is it also happens to be in trials against atopic dermatitis.

IMG-007’s alopecia areata trial participants will be dosed intravenously over the course of 6 months, and the study will be open label, meaning there is no placebo involved. More information about the trial, which is recruiting in October 2023, can be found on its official clinical trial listing.